Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As of May 01, 2026, Replimune Group, Inc. had a $206.4 million market capitalization, putting it in the 28th percentile of companies in the Biotechnology industry. Replimune Group, Inc. does not have ...

Rudrabhishek Enterprises Ltd is an integrated urban development & infrastructure consulting firm. The consultancy services include Viability Analysis, Infrastructure Services, Urban Planning, ...

Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...

Replimune Group ( (REPL)) has shared an announcement. On January 12, 2026, Replimune released an updated corporate presentation highlighting recent strategic developments and clinical data for its RP1 ...

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $12.82 / share. This is an increase of 10.52% from the prior estimate of $11.60 dated November 14, 2025. The ...

Investing.com - BMO Capital upgraded Replimune Group (NASDAQ:REPL) from Underperform to Market Perform and raised its price target to $11.00 from $2.00. The stock currently trades at $9.73, with the ...

Replimune Group (NASDAQ: REPL) Chief Financial Officer Emily Luisa Hill sold 9,154 shares of common stock on August 15, 2025, at a price of $5.37, for a total transaction value of $49,156.